Aatur Singhi, MD PhD

A tweetorial on our study (gastrojournal.org/article/S0016-…). But, first a case: Young female w/ a 1.9 cm incidental pancreatic cyst. No concerning features, but KRAS, TP53 and SMAD4 mutations on molecular testing. Surgical resection: #IPMN w/ a small #PancreaticCancer. #Pathology #GIPath

Great talk by Dr. Mallika Singh from Revolution Medicines at @nyulangone today, hosted by @NYUGSOM_Path chair @iannisaifantis1. A walk down memory lane on milestones in developing RAS tricomplex inhibitors, and the future (combinations that are ongoing & planned). @Perlmutter_CC

🚨@CureNETs LOI deadline is Monday, March 16th! Reach out with any questions.

KRAS inhibitors have been used to treat pancreatic cancer, but can they PREVENT cancer from occurring altogether? In @ScienceMagazine from @PennCancer Cancer interception with KRAS inhibitors in preclinical models of #PancreaticCancer science.org/doi/10.1126/sc…

@Aiims1742 @prenuvo That's a lot of cysts!!!

How often does @prenuvo whole body MRI find pancreatic cysts? >6% of the general population >20% of those >80y Most (96%) under 1cm Prevalence and Size-Based Risk Categorization of Pancreatic Cysts Among Asymptomatic Individuals With Screening MRI jamanetwork.com/journals/jaman…

Spatial transcriptomics needs to look beyond just mRNAs. Great to see this work from @ntekasi, Lena Takayasu, @IwijnDeVlaminck, and me in a past life out today!

Introducing Spatial ATAC-TAPS+ Following our AGBT 2026 presentation, we're excited to share our poster introducing our dual-modality spatial assay — developed in collaboration with Watchmaker Genomics, Matija Snuderl, and Ultima Genomics. Spatial ATAC-TAPS+ integrates chromatin accessibility and DNA methylation (5mC & 5hmC) profiling within the same tissue section, revealing regulatory heterogeneity that bulk assays miss. 📄 View the full poster: lnkd.in/e9MAiveY 🔬 Explore Spatial ATAC-TAPS+ and our broader spatial epigenomic platform at AtlasXomics.com #AGBT2026 #SpatialEpigenomics #DNAMethylation #ChromatinAccessibility

Tissue-specific basis for cancer evolution, as demonstrated with KRAS mutations nature.com/articles/s4158…

Xin Lu, PhD, describes the scientific foundations of a study of rezatapopt, which targets a variant form of p53, to treat patients with solid tumors. Learn about the science behind the study in the editorial “Restoring Function to a Variant of p53 in Solid Tumors,” from @Ludwig_Cancer: nej.md/3N0pQW8

When a phase 1 trial is published in @NEJM, you can bet it will be impactful. Here, the p53 reactivator rezatapopt showed an ORR 20% among 77 pts with TP53 mutant (Y220C) advanced tumors. Are we getting closer to drug the most undruggable of all mutations? nejm.org/doi/full/10.10…

In the recent GI publication search, we highlighted research by Andrew E Hendifar, Viswesh Krishna, @mnoel3232, @DavendraSohal,@graokane, @DrArsenOsipov, @tjroycemd, @anirrjoshi, @PancPathologist, Jennifer J Knox, and others, published in @JCO_ASCO. Read the complete list of journals- bit.ly/3OB6pDV.

@OncoThor It would be easier if the online version of the WHO 6th edition was free for all...

You wondering what's new in the WHO 6th Ed. of the classification of GI cancers...? The beta version is up on their website but you need to subscribe. Not in the mood for a long read on a subscription website...? You just want the skinny regarding changes...? Here you go! onlinelibrary.wiley.com/doi/full/10.11…

Beautiful illustration of the Frey Procedure. From the Cameron Atlas. @TomVargheseJr @juliomayol @SAGES_Updates

Screening works for colon cancer. Largest trial ever done. Today @NatureMedicine A randomized trial of colon cancer screening by colonoscopy or occult blood (FIT) vs control in nearly 280,000 participants showed signficantly more early diagnosis (stage I-II) and less stage III-IV cancers nature.com/articles/s4159…

@lh_innovations @UPMCHillmanCC @UPMC @UPMCHealthPlan @UPMCnews @PittHealthSci @PittGILiverNutr Less repeat ERCPs, increased early intervention, and modification of therapy based on informed analysis.

@PancPathologist @UPMCHillmanCC @UPMC @UPMCHealthPlan @UPMCnews @PittHealthSci @PittGILiverNutr BiliSeq's jump in sensitivity is real progress. Early actionable targets change patient management. How has this impacted workflow at your center?

Considering it's #WorldCholangiocarcinomaDay, it seems fitting to release some interesting results from our newest study on #BiliSeq (soon to be published), a combined clinically available DNA/RNA assay, akin to #PancreaSeq. A prospective study of >2,000 patients across the USA.

Today is World Cholangiocarcinoma Day 💚🌍 A rare cancer many hadn’t heard of until it changed their lives. Today we honor patients & caregivers, remember loved ones, and keep pushing for better answers together. Learn more: curecca.org #WorldCCADay #cureCCA

@Gio_Marchegiani @HalletJulie @PatricioPolanc0 @SocSurgOnc @Maker_MD @me4_so @Some4SurgeryIT1 @HpbLounge @hpb_trials @T4UGIS Great discussion. Disagree on the utility of cyst fluid biomarkers as an informed assay is needed: 1st evaluate the cyst (imaging is 1st biomarker), selecting those that need an EUS-FNA (fluid is the next) and blood to screening the fluid biomarker, which is in the NEAR future.

Management of Pancreatic Cystic Neoplasms 🍇 via cyst fluid analisys?! 🎙️ Nice debate with @HalletJulie @PatricioPolanc0 Thank you @SocSurgOnc for having me in your podcast and I already look forward to the #SSO2026 Phoenix 🏜️ congress! surgonctoday.libsyn.com/sso-education-…

@Aiims1742 The ATM results are very interesting. But it would be great to determine if current, clinical HRD assays (using WGS) can triage patients better for PARP inhibitors for #PancreaticCancer. Classifying variants is still challenging 😞

While bi-allelic loss of function of homologous recombination repair genes is not sufficient for sustained response to PARP inhibitors in #PancreaticCancer, it is at least necessary. Differentiation of mono v bi allelic LOF on molecular assays is a must. aacrjournals.org/clincancerres/…